SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
With the ongoing pandemic, it is critical to understand how natural immunity against SARS-CoV-2 and COVID-19 develops. We have identified that subjects with more severe COVID-19 disease mount a more robust and neutralizing antibody response against SARS-CoV-2 spike protein.
Article activity feed
-
-
SciScore for 10.1101/2020.09.12.294066: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Study cohorts: All studies were performed with the approval of the University of Chicago institutional review board and University of Chicago and University of Wisconsin-Madison institutional biosafety Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Horseradish peroxidase (HRP)-conjugated goat anti-human Ig secondary antibody diluted in PBS 0.1% Tween + 1% milk powder was used to detect binding of antibodies, and after a 1-hour incubation, plates were developed with 100 μl SigmaFast OPD solution … SciScore for 10.1101/2020.09.12.294066: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Study cohorts: All studies were performed with the approval of the University of Chicago institutional review board and University of Chicago and University of Wisconsin-Madison institutional biosafety Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Horseradish peroxidase (HRP)-conjugated goat anti-human Ig secondary antibody diluted in PBS 0.1% Tween + 1% milk powder was used to detect binding of antibodies, and after a 1-hour incubation, plates were developed with 100 μl SigmaFast OPD solution (Sigma-Aldrich), with development reaction stopped after 10 minutes using 50 μl 3M HCl. goat anti-human Ig secondary antibodysuggested: Noneanti-human Ig secondarysuggested: NoneExperimental Models: Cell Lines Sentences Resources D614G spike protein, SARS-CoV-1 RBD, and MERS-CoV RBD were generated in-house and expressed in HEK293F cells. HEK293Fsuggested: RRID:CVCL_6642)The plasma/virus mixture was incubated for 30 minutes at 37°C and added to TMPRSS2-expressing Vero E6 cells grown in 1x minimum essential medium (MEM) supplemented with 5% FCS. Vero E6suggested: RRID:CVCL_XD71)Experimental Models: Organisms/Strains Sentences Resources ORF7a, ORF8, and full-length N proteins were cloned from the 2019-nCoV/USA-WA1/2020 SARS-CoV-2 strain at Washington University. SARS-CoV-2suggested: NoneSoftware and Algorithms Sentences Resources All statistical analysis was performed using Prism software (Graphpad Version 8), JMP Prismsuggested: (PRISM, RRID:SCR_005375)Graphpadsuggested: (GraphPad, RRID:SCR_000306)(SAS Institute Version 15) SAS Institutesuggested: (Statistical Analysis System, RRID:SCR_008567)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04340050 Completed COVID-19 Convalescent Plasma Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
